Renalytix (LON:RENX) Stock Price Up 0.7% – Here’s Why

Renalytix Plc (LON:RENX) traded up 0.7% on Tuesday. The company traded as high as GBX 6.30 and last traded at GBX 6.19. Approximately 1,651,882 shares changed hands during trading, an increase of 52% from the average daily volume of 1,085,369 shares. The stock had previously closed at GBX 6.15.

Renalytix Stock Performance

The company has a debt-to-equity ratio of -483.33, a quick ratio of 2.42 and a current ratio of 1.57. The stock has a market capitalization of £25.38 million, a P/E ratio of -1.45 and a beta of 1.81. The business has a 50-day moving average price of GBX 4.47 and a 200 day moving average price of GBX 2.93.

Insider Transactions at Renalytix

In other Renalytix news, insider Christopher H. B. Mills sold 1,166,667 shares of the business’s stock in a transaction on Tuesday, September 29th. The stock was sold at an average price of GBX 6, for a total value of £70,000.02. Insiders own 5.14% of the company’s stock.

Renalytix Company Profile

Renalytix (LSE: RENX) (NASDAQ: RNLX) is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. The Company’s lead product is KidneyIntelX, which has been granted Breakthrough Designation by the U.S. Food and Drug Administration and which is being designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery (visit www.kidneyintelx.com).